title: Clinical features and outcomes of 49 Turkish patients with acute promyelocytic leukemia who received ATRA and anthracyclines (PETHEMA protocol) therapy.
authors.forename: Songul
authors.initials: S
authors.lastname: Serefhanoglu
authors.forename: Yahya
authors.initials: Y
authors.lastname: Buyukasik
authors.forename: Hakan
authors.initials: H
authors.lastname: Goker
authors.forename: Nilgun
authors.initials: N
authors.lastname: Sayinalp
authors.forename: Ibrahim Celalettin
authors.initials: IC
authors.lastname: Haznedaroglu
authors.forename: Salih
authors.initials: S
authors.lastname: Aksu
authors.forename: Osman Ilhami
authors.initials: OI
authors.lastname: Ozcebe
authors.forename: Mehmet
authors.initials: M
authors.lastname: Turgut
authors.forename: Rahmi
authors.initials: R
authors.lastname: Aslan
authors.forename: Evren
authors.initials: E
authors.lastname: Ozdemir
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D018943:Anthracyclines / Q000008:administration & dosage* / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D015255:Idarubicin / Q000008:administration & dosage / Q000009:adverse effects; D015473:Leukemia, Promyelocytic, Acute / Q000188:drug therapy* / Q000401:mortality*; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D015996:Survival Rate; D014212:Tretinoin / Q000008:administration & dosage* / Q000009:adverse effects; D014421:Turkey
chemical_list: D018943:Anthracyclines; D014212:Tretinoin; D015255:Idarubicin